Dr. Barbara S. Craft, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Mississippi School of Medicine (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 258
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: University of Mississippi School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MS license 18263
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mississippi Baptist Medical Center Jackson, MS
- University of Mississippi Med Center Jackson, MS
- St Dominic-Jackson Memorial Hospital Jackson, MS
- Merit Health Madison Canton, MS
Medical groups
- State of Mississippi - University of Mississippi Medical Center (965 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 258
- Services billed
- 509
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 303 | 208 |
| Established patient office or other outpatient visit, 40-54 minutes | 120 | 41 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 31 | 12 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 27 | 13 |
| New patient office or other outpatient visit, 60-74 minutes | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Jackson, MS | 283 |
| Anastrozole Other prescribers in Jackson, MS | 90 |
| Exemestane | 57 |
| Tamoxifen Citrate Other prescribers in Jackson, MS | 50 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Jackson, MS | 41 |
| Verzenio (abemaciclib) | 38 |
| Vitamin D2 (ergocalciferol (vitamin d2)) Other prescribers in Jackson, MS | 38 |
| Venlafaxine Hcl Er (venlafaxine hcl) Other prescribers in Jackson, MS | 37 |
| Ondansetron Hcl Other prescribers in Jackson, MS | 34 |
| Alendronate Sodium Other prescribers in Jackson, MS | 32 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 39 companies reported 140 payments worth $2,915 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $460 |
|---|---|
| Celgene Corporation | $196 |
| Novartis Pharmaceuticals Corporation | $194 |
| Gilead Sciences, Inc. | $164 |
| Incyte Corporation | $129 |
| Rigel Pharmaceuticals, Inc. | $107 |
| Merck Sharp & Dohme LLC | $102 |
| Pfizer Inc. | $100 |
| Food and Beverage | $2,908 |
|---|---|
| Education | $6.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Jan 7, 2025 | Education ENHERTU · Oncology · in-kind Company’s descriptionJournal Article | $6.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $101,273 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab MK-3475 Versus Treatment of Physician s Choice TPC in Participants With Triple-Negative…
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.